A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome

Diabetes

Volumn 54, Issue 3, 2005, Pages 591-602

  Summers, Scott A ^a   Nelson, Don H ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CERAMIDE DERIVATIVE; DEXAMETHASONE; FATTY ACID; GLUCOCORTICOID; PALMITIC ACID; PALMITOYL COENZYME A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SATURATED FATTY ACID; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CLINICAL FEATURE; CUSHING SYNDROME; DISEASE ASSOCIATION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFECTION SENSITIVITY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOGENESIS; METABOLIC SYNDROME X; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; WOUND HEALING IMPAIRMENT;

ANIMALS; CERAMIDES; CUSHING SYNDROME; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR STRUCTURE;

EID: 14644445144     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.3.591     Document Type: Review

References (189)

1. Hansen BC: The metabolic syndrome X. Ann N Y Acad Sci 892:1-24, 1999
2. Saltiel AR: New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517-529, 2001
3. Nelson DH: The adrenal cortex: physiologic function and disease. In Major Problems in Internal Medicine. Vol. 18. Smith LH, Ed. Toronto, Canada, Saunders, p. 281, 1980
4. Reich H, Nelson DH, Zaffaroni A: Isolation of 17-hydroxycorticosterone from blood obtained from adrenal veins of dogs. J Biol Chem 187:411-417, 1950
5. Unger RH: Minireview: Weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144:5159-5165, 2003
6. McGarry JD: Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7-18, 2002
7. Rajala MW, Scherer PE: Minireview: The adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144:3765-3773, 2003
8. Saltiel AR: You are what you secrete. Nat Med 7:887-888, 2001
9. Guerre-Millo M: Adipose tissue and adipokines: for better or worse. Diabetes Metab 30:13-19, 2004
10. Tappy L, Randin D, Vollenweider P, Vollenweider L, Paquot N, Scherrer U, Schneller P, Nicod P, Jequier E: Mechanisms of dexamethasone-induced insulin resistance in healthy humans. J Clin Endocrinol Metab 79:1063-1069, 1994
11. Pellacani A, Fornengo P, Bruno A, Ceruti C, Mioletti S, Curto M, Rinaudo MT, Pagano G, Cavallo-Perin P: Acute methylprednisolone administration induces a transient alteration of glucose tolerance and pyruvate dehydrogenase in humans. Eur J Clin Invest 29:861-867, 1999
12. Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, Fukushima Y, Onishi Y, Ono H, Fujishiro M, Kikuchi M, Oka Y, Asano T: Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction. Diabetes 49:1700-1708, 2000
13. Weinstein SP, Holand A, O'Boyle E, Haber RS: Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism 42:1365-1369, 1993
14. Weinstein SP, Paquin T, Pritsker A, Haber RS: Glucocorticoid-induced insulin resistance: dexamethasone inhibits the activation of glucose transport in rat skeletal muscle by both insulin- and non-insulin-related stimuli. Diabetes 44:441-445, 1995
15. Weinstein SP, Wilson CM, Pritsker A, Cushman SW: Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 47:3-6, 1998
16. Quintans J, Kilkus J, McShan CL, Gottschalk AR, Dawson G: Ceramide mediates the apoptotic response of WEHI 231 cells to anti- immunoglobulin, corticosteroids and irradiation. Biochem Biophys Res Commun 202:710-714, 1994
17. Nelson DH, Murray DK, Brady RO: Dexamethasone-induced change in the sphingomyelin content of human polymorphonuclear leukocytes in vitro. J Clin Endocrinol Metab 54:292-295, 1982
18. Kim MY, Linardic C, Obeid L, Hannun Y: Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon: specific role in cell differentiation. J Biol Chem 266:484-489, 1991
19. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M: Functional dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor signaling. Cell 78:1005-1015, 1994
20. Xu J, Yen CH, Chen S, He L, Sensi SL, Canzoniero LM, Choi DW, Hsu CY: Involvement of de novo ceramide biosynthesis in tumor necrosis factor-alpha/cycloheximide-induced cerebral endothelial cell death. J Biol Chem 273:16521-16526, 1998
21. Meyer SG, de Groot H: Cycloserine and threo-dihydrosphingosine inhibit TNF-alpha-induced cytotoxicity: evidence for the importance of de novo ceramide synthesis in TNF-alpha signaling. Biochim Biophys Acta 1643:1-4, 2003
22. Schmitz-Peiffer C, Craig DL, Bidn TJ: Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202-24210, 1999
23. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT, Florant GL, Summers SA: A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 13:10297-10303, 2003
24. Chavez JA, Summers SA: Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 419:101-109, 2003
25. Turinsky J, O'Sullivan DM, Bayly BP: 1,2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J Biol Chem 265:16880-16885, 1990
26. Gorska M, Dobrzyn A, Zendzian-Piotrowska M, Gorski J: Effect of streptozotocin-diabetes on the functioning of the sphingomyelin-signalling pathway in skeletal muscles of the rat. Horm Metab Res 36:14-21, 2004
27. Adams JM, 2nd, Pratipanawatr T, Berria R, Wang E, DeFronzo RA, Sullards MC, Mandarino LJ: Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53:25-31, 2004
28. Straczkowski M, Kowalska I, Nikolajuk A, Dzienis-Straczkowska S, Kinalska I, Baranowski M, Zendzian-Piotrowska M, Brzezinska Z, Gorski J: Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle. Diabetes 53:1215-1221, 2004
29. Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH Jr: Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 129:1239-1250, 1999
30. Merrill AH Jr: De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem 277:25843-25846, 2002
31. Rivellese AA, De Natale C, Lilli S: Type of dietary fat and insulin resistance. Ann N Y Acad Sci 967:329-335, 2002
32. Gorski J, Nawrocki A, Murthy M: Characterization of free and glyceride-esterified long chain fatty acids in different skeletal muscle types of the rat. Mol Cell Biochem 178:113-118, 1998
33. Shimabukuro M, Higa M, Zhou YT, Wang MY, Newgard CB, Unger RH: Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats: role of serine palmitoyltfansferase overexpression. J Biol Chem 273:32487-32490, 1998
34. Strelow A, Bernardo K, Adam-Klages S, Linke T, Sandhoff K, Kronke M, Adam D: Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J Exp Med 192:601-612, 2000
35. Saldeen J, Jaffrezou JP, Welsh N: The acid sphingomyelinase inhibitor SR33557 counteracts TNF-alpha-mediated potentiation of IL-1beta-induced NF-kappaB activation in the insulin-producing cell line Rinm5F. Autoimmunity 32:241-254, 2000
36. Andrieu-Abadie N, Levade T: Sphingomyelin hydrolysis during apoptosis. Biochim Biophys Acta 1585:126-134, 2002
37. Mathias S, Pena LA, Kolesnick RN: Signal transduction of ress via ceramide. Biochem J 335:465-480, 1998
38. Schutze S, Wiegmann K, Machleidt T, Kronke M: TNF-induced activation of NF-kappa B. Immunobiology 193:193-203, 1995
39. Nelson DH: Corticosteroid-induced changes in phospholipid membranes as mediators of their action. Endocr Rev 1:180-199, 1980
40. Nelson DH: The adrenal cortex: physiological function and disease. Major Probl Intern Med 18:iii-xii, 1-281, 1980
41. Murray DK, Ruhmann-Wennhold A, Nelson DH: Dexamethasone effect on the phospholipid content of isolated fat cell ghosts from adrenalectomized rats. Endocrinology 105:774-777, 1979
42. Johnston D, Matthews ER, Melnykovych G: Glucocorticoid effects on lipid metabolism in HeLa cells: inhibition of cholesterol synthesis and increased sphingomyelin synthesis. Endocrinology 107:1482-1488, 1980
43. Ramachandran CK, Murray DK, Nelson DH: Dexamethasone increases neutral sphingomyelinase activity and sphingosine levels in 3T3-L1 fibroblasts. Biochem Biophys Res Commun 167:607-613, 1990
44. Murray DK, Ruhmann-Wennhold A, Nelson DH: Adrenalectomy decreases the sphingomyelin and cholesterol content of fat cell ghosts. Endocrinology 111:452-455, 1982
45. Linn SC, Kim HS, Keane EM, Andras LM, Wang E, Merrill AH Jr: Regulation of de novo sphingolipid biosynthesis and the toxic consequences of its disruption. Biochem Soc Trans 29:831-835, 2001
46. Lepine S, Lakatos B, Maziere P, Courageot MP, Sulpice JC, Giraud F: Involvement of sphingosine in dexamethasone-induced thymocyte apoptosis. Ann N Y Acad Sci 973:190-193, 2002
47. Cifone MG, Migliorati G, Parroni R, Marchetti C, Millimaggi D, Santoni A, Riccardi C: Dexamethasone-induced thymocyte apoptosis: apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases. Blood 93:2282-2296, 1999
48. Dobrzyn A, Knapp M, Gorski J: Effect of acute exercise and training on metabolism of ceramide in the heart muscle of the rat. Acta Physiol Scand 181:313-319, 2004
49. Dobrzyn A, Zendzian-Piotrowska M, Gorski J: Effect of endurance training on the sphingomyelin-signalling pathway activity in the skeletal muscles of the rat. J Physiol Pharmacol 55:305-313, 2004
50. Helge JW, Dobrzyn A, Saltin B, Gorski J: Exercise and training effects on ceramide metabolism in human skeletal muscle. Exp Physiol 89:119-127, 2004
51. Whiteman EL, Cho H, Birnbaum MJ: Role, of Akt/protein kinase B in metabolism. Trends Endocrinol Metab 13:444-451, 2002
52. Nelson DH, Murray DK: Sphingolipids inhibit insulin and phorbol ester stimulated uptake of 2-deoxyglucose. Biochem Biophys Res Commun 138:463-467, 1986
53. Hajduch E, Balendran A, Batty IH, Litherland GJ, Blair AS, Downes CP, Hundal HS: Ceramide impairs the insulin-dependent membrane recruitment of protein kinase B leading to a loss in downstream signalling in L6 skeletal muscle cells. Diabetologia 44:173-183, 2001
54. Wang C-N, O'Brien L, Brindley DN: Effects of cell-permeable ceramides and tumor necrosis factor-α on insulin signaling and glucose uptake in 3T3-L1 adipocytes. Diabetes 47:24-31, 1998
55. Summers SA, Garza LA, Zhou H, Birnbaum MJ: Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 18:5457-5464, 1998
56. Kanety H, Hemi R, Papa MZ, Karasik A: Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 271:9895-9897, 1996
57. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM: Tumor necrosis factor (TNF-)-alpha inhibits insulin signaling through stimulation of the p-55 TNF-receptor and activation of sphirigomyelinase. J Biol Chem 271:13018-13022, 1996
58. Zundel W, Giaccia A: Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev 12:1941-1946, 1998
59. Kralik SF, Liu P, Leffler BJ, Elmendorf JS: Ceramide and glucosamine antagonism of alternate signaling pathways regulating insulin-and osmotic shock-induced glucose transporter 4 translocation. Endocrinology 143:37-46, 2002
60. Teruel T, Hernandez R, Lorenzo M: Ceramide mediates insulin resistance by tumor necrosis factor-α in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 50:2563-2571, 2001
61. Stratford S, DeWald DB, Summers SA: Ceramide dissociates 3′-phosphoinositide production from pleckstrin homology domain translocation. Biochem J 354:359-368, 2001
62. Stratford S, Hoehn KL, Liu F, Summers SA: Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 279:36608-36615, 2004
63. Powell DJ, Hajduch E, Kular G, Hundal HS: Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism. Mol Cell Biol 23:7794-7808, 2003
64. Salinas M, Lopez-Valdaliso R, Martin D, Alvarez A, Cuadrado A: Inhibition of PKB/Aktl by C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol Cell Neurosci 15:156-169, 2000
65. Zinda MJ, Vlahos CJ, Lai MT: Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells. Biochem Biophys Res Commun 280:1107-1115, 2001
66. Cazzolli R, Carpenter L, Biden TJ, Schmitz-Peiffer C: A role for protein phosphatase 2A-like activity, but not atypical protein kinase Cζ, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes 50:2210-2218, 2001
67. Long SD, Pekala PH: Lipid mediators of insulin resistance: ceramide signalling down regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 319:179-184, 1996
68. Hunnicutt JW, Hardy RW, Williford J, McDonald JM: Saturated fatty acid-induced insulin resistance in rat adipocytes. Diabetes 43:540-545, 1994
69. Montell E, Turini M, Marotta M, Roberts M, Noe V, Ciudad CJ, Mace K, Gomez-Foix AM: DAG accumulation from saturated fatty acids desensitizes insulin stimulation of glucose uptake in muscle cells. Am J Physiol Endocrinol Metab 280:E229-E237, 2001
70. Storz P, Doppler H, Wernig A, Pfizenmaier K, Muller G: Cross-talk mechanisms in the development of insulin resistance of skeletal muscle cells palmitate rather than tumour necrosis factor inhibits insulin-dependent protein kinase B (PKB)/Akt stimulation and glucose uptake. Eur J Biochem 266:17-25, 1999
71. Thompson AL, Lim-Fraser MY, Kraegen EW, Cooney GJ: Effects of individual fatty acids on glucose uptake and glycogen synthesis in soleus muscle in vitro. Am J Physiol Endocrinol Metab 279:E577-E584, 2000
72. Bachmann OP, Dahl DB, Brechtel K, Machann J, Haap M, Maier T, Loviscach M, Stumvoll M, Claussen CD, Schick F, Haring HU, Jacob S: Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 50:2579-2584, 2001
73. 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents: relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 51:1022-1027, 2002
74. Neschen S, Moore I, Regittnig W, Yu CL, Wang Y, Pypaert M, Petersen KF, Shulman GI: Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content. Am J Physiol Endocrinol Metab 282:E395-E401, 2002
75. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51:2005-2011, 2002
76. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI: Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98:7522-7527, 2001
77. Ferreira LD, Pulawa LK, Jensen DR, Eckel RH: Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 50:1064-1068, 2001
78. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI: Mechanism by which fatty acids inhibit insulin activation of IRS-1 associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277:50230-50236, 2002
79. Kim YB, Shulman GI, Kahn BB: Fatty acid infusion selectively impairs insulin action on Akt1 and protein kinase C lambda/zeta but not on glycogen synthase kinase-3. J Biol Chem 277:32915-32922, 2002
80. Hodgkin MN, Pettitt TR, Martin A, Michell RH, Pemberton AJ, Wakelam MJ: Diacylglycerols and phosphatidates: which molecular species are intracellular messengers? Trends Biochem Sci 23:200-204, 1998
81. Wakelam MJ: Diacylglycerol: when is it an intracellular messenger? Biochim Biophys Acta 1436:117-126, 1998
82. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB: The expression of tumor necrosis factor in human adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95:2111-2119, 1995
83. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43-52, 1992
84. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87-91, 1993
85. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA: The expression of TNF-alpha by human muscle: relationship to insulin resistance. J Clin Invest 97:1111-1116, 1996
86. Uysal KT, Wiesbrock SM, Marino WM, Hotamisligil GS: Protection from obesity-induced insulin resistance in mice lacking TNF-a function. Nature 389:610-614, 1997
87. Uysal KT, Wiesbrock SM, Hotamisligil GS: Functional analysis of tumor necrosis factor (TNF-) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 139:4832-4838, 1998
88. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45:881-885, 1996
89. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 91:4854-4858, 1994
90. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668, 1996
91. Stephens JM, Lee J, Pilch PF: Tumor necosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem 272:971-976, 1997
92. Carter-Su C, Okamoto K: Effect of glucocorticoids on hexose transport in rat adipocytes: evidence for decreased transporters in the plasma membrane. J Biol Chem 260:11091-11098, 1985
93. Carter-Su C, Okamoto K: Inhibition of hexose transport in adipocytes by dexamethasone: role of protein synthesis. Am J Physiol 248:E215-E223, 1985
94. Carter-Su C, Okamoto K: Effect of insulin and glucocorticoids on glucose transporters in rat adipocytes. Am J Physiol 252:E441-E453, 1987
95. Oda N, Nakai A, Mokuno T, Sawai Y, Nishida Y, Mano T, Asano K, Itoh Y, Kotake M, Kato S, et al: Dexamethasone-induced changes in glucose transporter 4 in rat heart muscle, skeletal muscle and adipocytes. Eur J Endocrinol 133:121-126, 1995
96. Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeanrenaud B: Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia 36:899-906, 1993
97. Coderre L, Srivastava AK, Chiasson JL: Effect of hypercorticism on regulation of skeletal muscle glycogen metabolism by insulin. Am J Physiol 262:E427-E433, 1992
98. Daw JC, Lefer AM, Berne RM: Influences of corticosteroids on cardiac glycogen concentration in the rat. Circ Res 22:639-647, 1968
99. Turnbow M, Keller S, Rice K, Garner C: Dexamethasone down-regulation of insulin receptor substrate-1 in 3T3-L1 adipocytes. J Biol Chem 269:2516-2520, 1994
100. Buren J, Liu HX, Jensen J, Eriksson JW: Dexamethasone impairs insulin signalling and glucose transport by depletion of insulin receptor substrate-1, phosphatidylinositol 3-kinase and protein kinase B in primary cultured rat adipocytes. Eur J Endocrinol 146:419-429, 2002
101. Saad MJ, Folli F, Kahn JA, Kahn CR: Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92:2065-2072, 1993
102. Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall'omo AM, Imbimbo B: An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 72:1814-1820, 1983
103. Beck-Nielsen H, De Pirro R, Pedersen O: Prednisone increases the number of insulin receptors on monocytes from normal subjects. J Clin Endocrinol Metab 50:1-4, 1980
104. Saad MJ, Folli F, Araki E, Hashimoto N, Csermely P, Kahn CR: Regulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in 3T3-F442A adipocytes: effects of differentiation, insulin, and dexamethasone. Mol Endocrinol 8:545-557, 1994
105. Saad MJ, Folli F, Kahn CR: Insulin and dexamethasone regulate insulin receptors, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in Fao hepatoma cells. Endocrinology 136:1579-1588, 1995
106. Giorgino F, Almahfouz A, Goodyear LJ, Smith RJ: Glucocorticoid regulation of insulin receptor and substrate IRS-1 tyrosine phosphorylation in rat skeletal muscle in vivo. J Clin Invest 91:2020-2030, 1993
107. Long W, Barrett EJ, Wei L, Liu Z: Adrenalectomy enhances the insulin sensitivity of muscle protein synthesis. Am J Physiol Endocrinol Metab 284:E102-E109, 2003
108. Shah OJ, Anthony JC, Kimball SR, Jefferson LS: Glucocorticoids oppose translational control by leucine in skeletal muscle. Am J Physiol Endocrinol Metab 279:E1185-E1190, 2000
109. Shah OJ, Kimball SR, Jefferson LS: Glucocorticoids abate p70(S6k) and eIF4E function in L6 skeletal myoblasts. Am J Physiol Endocrinol Metab 279:E74-E82, 2000
110. Olefsky JM: Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 56:1499-1508, 1975
111. Fernandez BM, Saggerson ED: Alterations in response of rat white adipocytes to insulin, noradrenaline, corticotropin and glucagon after adrenalectomy: correction of these changes by adenosine deaminase. Biochem J 174:111-118, 1978
112. Nelson DH, Murray DK: Dexamethasone increases the synthesis of sphingomyelin in 3T3-L1 cell membranes. Proc Natl Acad Sci U S A 79:6690-6692, 1982
113. Murray DK, Hill ME, Nelson DH: Inhibitory action of sphingosine, sphinganine and dexamethasone on glucose uptake: studies with hydrogen peroxide and phorbol ester. Life Sci 46:1843-1849, 1990
114. Hoff HF, Morton RE: Lipoproteins containing apo B extracted from human aortas: structure and function. Ann N Y Acad Sci 454:183-194, 1985
115. Guyton JR, Hemp KF: Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 16:4-11, 1996
116. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I: Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained low-density lipoprotein: proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest 98:1455-1464, 1996
117. Holopainen JM, Lehtonen JY, Kinnunen PK: Lipid microdomains in dimyristoylphosphatidylcholine-ceramide liposomes. Chem Phys Lipids 88:1-13, 1997
118. Holopainen JM, Lemmich J, Richter F, Mouritsen OG, Rapp G, Kinnunen PK: Dimyristoylphosphatidylcholine/C16:0-ceramide binary liposomes studied by differential scanning calorimetry and wide- and small-angle x-ray scattering. Biophys J 78:2459-2469, 2000
119. Kinnunen PK, Holopainen JM: Sphingomyelinase activity of LDL: a link between atherosclerosis, ceramide, and apoptosis? Trends Cardiovasc Med 12:37-42, 2002
120. Auge N, Negre-Salvayre A, Salvayre R, Levade T: Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog Lipid Res 39:207-229, 2000
121. Levade T, Auge N, Veldman RJ, Cuvillier O, Negre-Salvayre A, Salvayre R: Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res 89:907-968, 2001
122. Mallat Z, Tedgui A: Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol 130:947-962, 2000
123. Mallat Z, Tedgui A: Current perspective on the role of apoptosis in atherothrombotic disease. Circ Res 88:998-1003, 2001
124. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH: Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:1784-1789, 2000
125. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, Sano T, Satoh K, Kume S, Tigyi G, Igarashi Y, Ozaki Y: Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96:3431-3438, 2000
126. Auge N, Nikolova-Karakashian M, Carpentier S, Parthasarathy S, Negre-Salvayre A, Salvayre R, Merrill AH Jr, Levade T: Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J Biol Chem 274:21533-21538, 1999
127. Chatterjee S: Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 18:1523-1533, 1998
128. Bhatia R, Matsushita K, Yamakuchi M, Morrell CN, Cao W, Lowenstein CJ: Ceramide triggers Weibel-Palade body exocytosis. Circ Res 95:319-324, 2004
129. Soeda S, Honda O, Shimeno H, Nagamatsu A: Sphingomyelinase and cell-permeable ceramide analogs increase the release of plasminogen activator inhibitor-1 from cultured endothelial cells. Thromb Res 80:509-518, 1995
130. Hirokawa M, Kitabayashi A, Kuroki J, Miura AB: Induction of tissue factor production but not the upregulation of adhesion molecule expression by ceramide in human vascular endothelial cells. Tohoku J Exp Med 191:167-176, 2000
131. Constable PD, Smith GW, Rottinghaus GE, Tumbleson ME, Haschek WM: Fumonisin-induced blockade of ceramide synthase in sphingolipld biosynthetic pathway alters aortic input impedance spectrum of pigs. Am J Physiol Heart Circ Physiol 284:H2034-E2044, 2003
132. Kronke M: Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes. Chem Phys Lipids 101:109-121, 1999
133. Dorrance AM, Graham D, Webb RC, Fraser R, Dominiczak A: Increased membrane sphingomyelin and arachidonic acid In stroke-prone spontaneously hypertensive rats. Am J Hypertens 14:1149-1153, 2001
134. Zheng T, Li W, Wang J, Altura BT, Altura BM: Sphingomyelinase and ceramide analogs induce contraction and rises in [Ca(2+)](i) in canine cerebral vascular muscle. Am J Physiol Heart Circ Physiol 278:H1421-H1428, 2000
135. Murohara T, Kugiyama K, Ohgushi M, Sugiyama S, Ohta Y, Yasue H: Effects of sphingomyelinase and sphingosine on arterial vasomotor regulation. J Lipid Res 37:1601-1608, 1996
136. Bischoff A, Czyborra P, Fetscher C, Meyer Zu Heringdorf D, Jakobs KH, Michel MC: Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro. Br J Pharmacol 130:1871-1877, 2000
137. Todoroki-Ikeda N, Mizukami Y, Mogami K, Kusuda T, Yamamoto K, Miyake T, Sato M, Suzuki S, Yamagata H, Hokazono Y, Kobayashi S: Sphingosylphosphorylcholine induces Ca(2+)-sensltization of vascular smooth muscle contraction: possible involvement of rho-kinase. FEBS Lett 482:85-90, 2000
138. Bischoff A, Czyborra P, Meyer Zu Heringdorf D, Jakobs KH, Michel MC: Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner. Br J Pharmacol 130:1878-1883, 2000
139. Bolz SS, Vogel L, Sollinger D, Derwand R, Boer C, Pitson SM, Spiegel S, Pohl U: Sphingosine kinase modulates microvascular tone and myogenic responses through activation of RhoA/Rho kinase. Circulation 108:342-347, 2003
140. Johns DG, Webb RC: TNF-alpha-induced endothelium-independent vasodilation: a role for phospholipase A2-dependent ceramide signaling. Am J Physiol 275:H1592-H1598, 1998
141. Zhang DX, Yi FX, Zou AP, Li PL: Role of ceramide in TNF-alpha-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. Am J Physiol Heart Circ Physiol 283:H1785-H1794, 2002
142. Zheng T, Li W, Wang J, Altura BT, Altura BM: C2-ceramide attenuates phenylephrine-induced vasoconstriction and elevation in [Ca2+]i in rat aortic smooth muscle. Lipids 34:689-695, 1999
143. Yang S, Zhang L: Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol 2:1-12, 2004
144. Mitchell BM, Webb RC: Impaired vasodilation and nitric oxide synthase activity in glucocorticoid-induced hypertension. Biol Res Nurs 4:16-21, 2002
145. Iuchi T, Akaike M, Mitsui T, Ohshima Y, Shintani Y, Azuma H, Matsumoto T: Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ Res 92:81-87, 2003
146. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM: Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656-1662, 2002
147. Zhang DX, Zou AP, Li PL: Ceramide reduces endothelium-dependent vasodilation by increasing superoxide production in small bovine coronary arteries. Circ Res 88:824-831, 2001
148. Franzen R, Fabbro D, Aschrafi A, Pfeilschifter J, Huwiler A: Nitric oxide induces degradation of the neutral ceramidase in rat renal mesangial cells and is counterregulated by protein kinase C. J Biol Chem 277:46184-46190, 2002
149. Huwiler A, Dorsch S, Briner VA, van den Bosch H, Pfeilschifter J: Nitric oxide stimulates chronic ceramide formation in glomerular endothelial cells. Biochem Biophys Res Commun 258:60-65, 1999
150. Pautz A, Franzen R, Dorsch S, Boddinghaus B, Briner VA, Pfeilschifter J, Huwiler A: Cross-talk between nitric oxide and superoxide determines ceramide formation and apoptosis in glomerular cells. Kidney Int 61:790-796, 2002
151. Gulbins E, Kolesnick R: Raft ceramide in molecular medicine. Oncogene 22:7070-7077, 2003
152. Manes S, del Real G, Martinez AC: Pathogens: raft hijackers. Nat Rev Immunol 3:557-568, 2003
153. Simons K, Ehehalt R: Cholesterol, lipid rafts, and disease. J Clin Invest 110:597-603, 2002
154. Chazal N, Gerlier D: Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev 67:226-237, 2003
155. Gulbins E, Dreschers S, Wilker B, Grassme H: Ceramide, membrane rafts and infections. J Mol Med 82:357-363, 2004
156. Grassme H, Gulbins E, Brenner B, Ferlinz K, Sandhoff K, Harzer K, Lang F, Meyer TF: Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 91:605-615, 1997
157. Hauck CR, Grassme H, Bock J, Jendrossek V, Ferlinz K, Meyer TF, Gulbins E: Acid sphingomyelinase is involved in CEACAM receptor-mediated phagocytosis of Neisseria gonorrhoeae. FEBS Lett 478:260-266, 2000
158. Esen M, Schreiner B, Jendrossek V, Lang F, Fassbender K, Grassme H, Gulbins E: Mechanisms of Staphylococcus aureus induced apoptosis of human endothelial cells. Apoptosis 6:431-439, 2001
159. Jan JT, Chatterjee S, Griffin DE: Sindbis virus entry into cells triggers apoptosis by activating sphingomyelinase, leading to the release of ceramide. J Virol 74:6425-6432, 2000
160. Ghosh S, Bhattacharyya S, Das S, Raha S, Maulik N, Das DK, Roy S, Majumdar S: Generation of ceramide in murine macrophages infected with Leishmania donovani alters macrophage signaling events and aids intracellular parasitic survival. Mol Cell Biochem 223:47-60, 2001
161. Soory M: Hormone mediation of immune responses in the progression of diabetes, rheumatoid arthritis and periodontal diseases. Curr Drug Targets Immune Endocr Metabol Disord 2:13-25, 2002
162. Mandell GL, Rubin W, Hook EW: The effect of an NADH oxidase inhibitor (hydrocortisone) on polymorphonuclear leukocyte bactericidal activity. J Clin Invest 49:1381-1388, 1970
163. Nelson DH, Meikle AW, Benowitz B, Murray DK, Ruhmann-Wennhold A: Cortisol and dexamethasone suppression of superoxide anion production by leukocytes from normal subjects. Trans Assoc Am Physicians 91:381-387, 1978
164. Mansfield PJ, Hinkovska-Galcheva V, Carey SS, Shayman JA, Boxer LA: Regulation of polymorphonuclear leukocyte degranulation and oxidant production by ceramide through inhibition of phospholipase D. Blood 99:1434-1441, 2002
165. Suchard SJ, Hinkovska-Galcheva V, Mansfield PJ, Boxer LA, Shayman JA: Ceramide inhibits IgG-dependent phagocytosis in human polymorphonuclear leukocytes. Blood 89:2139-2147, 1997
166. Hinkovska-Galcheva V, Kjeldsen L, Mansfield PJ, Boxer LA, Shayman JA, Suchard SJ: Activation of a plasma membrane-associated neutral sphingomyelinase and concomitant ceramide accumulation during IgG-dependent phagocytosis in human polymorphonuclear leukocytes. Blood 91:4761-4769, 1998
167. Nakamura T, Abe A, Balazovich KJ, Wu D, Suchard SJ, Boxer LA, Shayman JA: Ceramide regulates oxidant release in adherent human neutrophils. J Biol Chem 269:18384-18389, 1994
168. Ballou LR, Chao CP, Holness MA, Barker SC, Raghow R: Interleukin-1- mediated PGE2 production and sphingomyelin metabolism: evidence for the regulation of cyclooxygenase gene expression by sphingosine and ceramide. J Biol Chem 267:20044-20050, 1992
169. Ballou LR, Laulederkind SJ, Rosloniec EF, Raghow R: Ceramide signalling and the immune response. Biochim Biophys Acta 1301:273-287, 1996
170. Candela M, Barker SC, Ballou LR: Sphingosine synergistically stimulates tumor necrosis factor alpha-induced prostaglandin E2 production in human fibroblasts. J Exp Med 174:1363-1369, 1991
171. Cinque B, Di Marzio L, Centi C, Di Rocco C, Riccardi C, Grazia Cifone M: Sphingolipids and the immune system. Pharmacol Res 47:421-437, 2003
172. Hevener AL, Reichart D, Janez A, Olefsky J: Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male wistar rats. Diabetes 50:2316-2322, 2001
173. Chang AY, Wyse BM, Gilchrist BJ, Peterson T, Diani AR: Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats. Diabetes 32:830-838, 1983
174. Yen TT, Gill AM, Powell JG, Sampson BM: Ciglitazone prevents and reverses dexamethasone-induced hyperglycemia in female viable yellow mice. Int J Obes Relat Metab Disord 16:923-933, 1992
175. Dandona P, Aljada A: Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents. J Diabetes Complications 18:91-102, 2004
176. Dandona P, Aljada A, Chaudhuri A: Vascular reactivity and thiazolidinediones. Am J Med 115 (Suppl. 8A):81S-86S, 2003
177. Hsueh WA, Bruemmer D: Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. Hypertension 43:297-305, 2004
178. Rangwala SM, Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25:331-336, 2004
179. Hevener AL, He W, Barak Y, Le J, Bandyopadhyay G, Olson P, Wilkes J, Evans RM, Olefsky J: Muscle-specific PPAR-g deletion causes insulin resistance. Nat Med 9:1491-1497, 2003
180. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM, Kahn CR: Muscle-specific PPAR-gamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 112:608-618, 2003
181. Szalkowski D, White-Carrington S, Berger J, Zhang B: Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression m 3T3-L1 cells. Endocrinology 136:1474-1481, 1995
182. Peraldi P, Xu M, Spiegelman BM: Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 100:1863-1869, 1997
183. Solomon SS, Usdan LS, Palazzolo MR: Mechanisms involved in tumor necrosis factor-alpha induction of insulin resistance and its reversal by thiazolidinedione(s). Am J Med Sci 322:75-78, 2001
184. Zeghari N, Vidal H, Younsi M, Ziegler O, Drouin P, Donner M: Adipocyte membrane phospholipids and PPAR-gamma expression in obese women: relationship to hyperinsulinemia. Am J Physiol Endocrinol Metab 279:E736-E743, 2000
185. Al-Makdissy N, Bianchi A, Younsi M, Picard E, Valet P, Martinet N, Dauca M, Donner M: Down-regulation of peroxisome proliferator-activated receptor-gamma gene expression by sphingomyelins. FEBS Lett 493:75-79, 2001
186. Sprott KM, Chumley MJ, Hanson JM, Dobrowsky RT: Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein beta during inhibition of adipogenesis by ceramide. Biochem J 365:181-191, 2002
187. Van Veldhoven PP, Mannaerts GP, Declercq P, Baes M: Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)? Cell Signal 12:475-479, 2000
188. Hannun YA, Obeid LM: The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 277:25847-25850, 2002
189. Van Blitterswyk WJ, Van Der Luit AH, Veldman RJ, Verheij M, Borst J: Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem J 369:199-211, 2003